Overview

A Chronic Pain Master Protocol (CPMP): A Study of LY3857210 in Participants With Diabetic Peripheral Neuropathic Pain (NP05)

Status:
Not yet recruiting

Trial end date:
2023-10-30

Target enrollment:

Participant gender:

Summary

This study is being done to test the safety and efficacy of the study drug LY3852710 for the treatment of diabetic peripheral neuropathic pain.

Phase:

Phase 2

Details

Lead Sponsor:

Eli Lilly and Company